MAXCYTE Files 8-K on Financial Condition & Operations
Ticker: MXCT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1287098
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, corporate-filing
TL;DR
**MAXCYTE just dropped an 8-K on financial results, get ready for new numbers.**
AI Summary
MAXCYTE, INC. filed an 8-K on January 8, 2024, to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that the company is providing an update on its financial performance and related disclosures. For investors, this matters because it signals that new financial information is being made public, which could influence the stock's valuation and future prospects.
Why It Matters
This filing indicates that MAXCYTE, INC. is releasing new financial information, which is crucial for investors to assess the company's health and make informed decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not an event that inherently carries high risk.
Analyst Insight
Investors should look for the actual financial statements and results that this 8-K refers to, as this filing itself is merely a notification of their release. The specific details within those financial documents will dictate any investment action.
Key Numbers
- January 8, 2024 — Date of Report (The date the earliest event reported in the 8-K occurred and the filing date.)
- 001-40674 — Commission File Number (Unique identifier for MAXCYTE, INC. with the SEC.)
- MXCT — Trading Symbol (The ticker symbol under which MAXCYTE, INC. Common Stock is traded.)
- $0.01 — Par Value (The stated par value per share of MAXCYTE, INC.'s Common Stock.)
Key Players & Entities
- MAXCYTE, INC. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for MaxCyte, Inc.
- 001-40674 (dollar_amount) — Commission File Number
- 52-2210438 (dollar_amount) — IRS Employer Identification No.
- 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 (company) — address of principal executive offices
- 301-944-1700 (dollar_amount) — registrant's telephone number
- MXCT (company) — trading symbol for Common Stock
- $0.01 (dollar_amount) — par value of Common Stock
FAQ
What is the primary purpose of this 8-K filing by MAXCYTE, INC.?
The primary purpose of this 8-K filing by MAXCYTE, INC. is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of January 8, 2024.
What is the trading symbol for MAXCYTE, INC. Common Stock?
The trading symbol for MAXCYTE, INC. Common Stock, with a $0.01 par value, is MXCT.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is the state of incorporation for MaxCyte, Inc.?
MaxCyte, Inc. is incorporated in Delaware.
What is the business address of MaxCyte, Inc. as stated in the filing?
The business address of MaxCyte, Inc. is 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-08 16:15:36
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20240108x8k.htm (8-K) — 37KB
- mxct-20240108xex99d1.htm (EX-99.1) — 24KB
- mxct-20240108xex99d1001.jpg (GRAPHIC) — 7KB
- 0001558370-24-000136.txt ( ) — 195KB
- mxct-20240108.xsd (EX-101.SCH) — 3KB
- mxct-20240108_lab.xml (EX-101.LAB) — 16KB
- mxct-20240108_pre.xml (EX-101.PRE) — 10KB
- mxct-20240108x8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, MaxCyte, Inc. (the " Company ") issued a press release announcing preliminary financial results for the quarter and fiscal year ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instructions B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated January 8, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: January 8, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer